Literature DB >> 11880394

Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.

Marcel Beld1, Roel Sentjens, Sjoerd Rebers, Christine Weegink, Jan Weel, Cees Sol, René Boom.   

Abstract

We have evaluated the VERSANT HCV RNA 3.0. Assay (HCV 3.0 bDNA assay) (Bayer Diagnostics, Berkeley, Calif.), which is an improved signal amplification procedure for the HCV 2.0 bDNA assay for the quantitation of hepatitis C virus (HCV) RNA in serum or plasma of HCV-infected individuals. The HCV 3.0 bDNA assay has a linear dynamic range of 2.5 x 10(3) to 4.0 x 10(7) HCV RNA copies per ml (c/ml). The performance of the HCV 3.0 bDNA assay was evaluated using three different test panels. An overall specificity of 96.8% relative to the detection limit of the HCV 3.0 bDNA assay was found. The intra- and interrun reproducibilities for both the dilution panel and the NAP (AcroMetrix, Benicia, Calif.) panel were consistent with coefficients of variation of less than 9%. Quantitation with the HCV 3.0 bDNA assay was linear over the entire range of both panels (ranges of 4.4 x 10(3) to 3.5 x 10(6) c/ml and 5 x 10(3) to 2 x 10(6) IU/ml, respectively), with correlation coefficients of 0.999, slopes close to one, and intercepts close to zero. The regression equation indicated that 1 IU corresponded to about 4.8 copies of HCV RNA. A correlation coefficient of 0.941 was found for HCV RNA values (in international units per milliliter) obtained from the HCV 3.0 bDNA assay and the HCV Monitor version 2.0 assay (HCV Monitor 2.0 assay) (Roche Diagnostic Systems, Branchburg, N.J.). Quantitative results obtained close to the lower limit of the HCV 3.0 bDNA assay might imply that its lower limit should be reconsidered and raised, if necessary. It appeared that quantitation values obtained from the HCV Monitor 2.0 assay of between 5 x 10(2) and 10(5) IU/ml were in general higher than those obtained from the HCV 3.0 bDNA assay, whereas values obtained from the HCV Monitor 2.0 assay were underestimated for samples with HCV RNA levels above 10(5) IU/ml.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880394      PMCID: PMC120248          DOI: 10.1128/JCM.40.3.788-793.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

Review 1.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

2.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

3.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

4.  Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.

Authors:  S Zeuzem; J H Lee; A Franke; B Rüster; O Prümmer; G Herrmann; W K Roth
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

5.  Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.

Authors:  J Mellor; A Hawkins; P Simmonds
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

7.  Standardization of hepatitis C virus RNA quantification.

Authors:  J M Pawlotsky; M Bouvier-Alias; C Hezode; F Darthuy; J Remire; D Dhumeaux
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

8.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Authors:  J Detmer; R Lagier; J Flynn; C Zayati; J Kolberg; M Collins; M Urdea; R Sánchez-Pescador
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Standardized hepatitis C virus RNA panels for nucleic acid testing assays.

Authors:  P A Jorgensen; P D Neuwald
Journal:  J Clin Virol       Date:  2001-01       Impact factor: 3.168

10.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

View more
  19 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens.

Authors:  Jan Felix Drexler; Ulrike Reber; Andrea Wuttkopf; Anna Maria Eis-Hübinger; Christian Drosten
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

3.  Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Authors:  Chihiro Morishima; Minjun Chung; Ka Wing Ng; Donald J Brambilla; David R Gretch
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 4.  Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection.

Authors:  C L Cooper; Curtis L Cooper; Paul MacPherson; William Cameron
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

5.  Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.

Authors:  Peter A White; Yong Pan; Anthony J Freeman; George Marinos; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.

Authors:  Isabelle Desombere; Hans Van Vlierberghe; Sibyl Couvent; Filip Clinckspoor; Geert Leroux-Roels
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus.

Authors:  Nahed Ismail; Geoffrey E Fish; Michael B Smith
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

8.  Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).

Authors:  Tarek Elbeik; Johan Surtihadi; Mark Destree; Jed Gorlin; Mark Holodniy; Saeed A Jortani; Ken Kuramoto; Valerie Ng; Roland Valdes; Alexandra Valsamakis; Norah A Terrault
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

9.  Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay.

Authors:  Joseph D C Yao; Marcel G H M Beld; Lynette Lin Ean Oon; Christopher H Sherlock; Jeffrey Germer; Sandra Menting; Su Yun Se Thoe; Linda Merrick; Rainer Ziermann; Johan Surtihadi; H James Hnatyszyn
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

10.  Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.

Authors:  Christoph Sarrazin; Barbara C Gärtner; Dorothea Sizmann; Rainer Babiel; Ulrike Mihm; Wolf Peter Hofmann; Michael von Wagner; Stefan Zeuzem
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.